Analysis Tools
normal phenotype
|
• mice are viable and exhibit not visible abnormalities and remain healthy throughout 12 months of study, with normal lungs
|
|
Allele Symbol Allele Name Allele ID |
Scgb1a1tm1.1(cre)Fjd targeted mutation 1.1, Franco J DeMayo MGI:3797250 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are viable and exhibit not visible abnormalities and remain healthy throughout 12 months of study, with normal lungs
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• average survival is 24 weeks
|
|
• mutants develop lung lesions that are first detected at 12 weeks of age in alveoli and bronchioles
• mutants develop epithelial lesions termed atypical papillary bronchiolar proliferation that has papillary proliferations of the bronchiolar epithelium located at the bronchiolar terminal site
|
|
• atypical adenomatous hyperplasia lesions and adenomas
|
|
• mutants develop lung lesions that are first detected at 12 weeks of age in alveoli and bronchioles
• mutants develop epithelial lesions termed atypical papillary bronchiolar proliferation that has papillary proliferations of the bronchiolar epithelium located at the bronchiolar terminal site
• however, no carcinomas are seen by 24 weeks of age
|
|
• mutants develop lung lesions that are first detected at 12 weeks of age in alveoli and bronchioles
• mutants develop epithelial lesions termed atypical papillary bronchiolar proliferation that has papillary proliferations of the bronchiolar epithelium located at the bronchiolar terminal site
|
|
• atypical adenomatous hyperplasia lesions and adenomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean survival is 8 weeks
|
|
• increase in inflammation in lesions compared to single Kras mutants, with an increase in neutrophil and endothelial cell infiltration; infiltration of these cells increases with malignant progression
|
|
• increase in inflammation in lesions compared to single Kras mutants, with an increase in neutrophil and endothelial cell infiltration; infiltration of these cells increases with malignant progression
|
|
• mutants have higher numbers of lesions and more extensive tumors than single Kras mutants
• mutants develop distinct bronchial and alveolar tumors
|
|
• mutants develop lung lesions as early as 4 weeks of age including proliferative atypical adenomatous hyperplasia lesions
|
|
• mutants develop lung lesions as early as 4 weeks of age that includes atypical papillary bronchiolar proliferation
|
|
• mucinous bronchioloalveolar cell carcinoma-like lesions, a subtype of lung adenocarcinoma
|
|
• mutants have higher numbers of lesions and more extensive tumors than single Kras mutants
• mutants develop distinct bronchial and alveolar tumors
|
|
• mutants develop lung lesions as early as 4 weeks of age including proliferative atypical adenomatous hyperplasia lesions
|
|
• mutants develop lung lesions as early as 4 weeks of age that includes atypical papillary bronchiolar proliferation
|
|
• mucinous bronchioloalveolar cell carcinoma-like lesions, a subtype of lung adenocarcinoma
|
|
• by 2 months of age, mutants exhibit weight loss
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice are viable and fertile with normal lung morphology
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 07/05/2024 MGI 6.24 |
|
|
|
||